Chinese Journal of Stroke ›› 2016, Vol. 11 ›› Issue (08): 697-703.
Previous Articles Next Articles
Received:
2016-04-05
Online:
2016-08-20
Published:
2016-08-20
林露,张猛
通讯作者:
张猛 zhangmeng861@gmail.com
基金资助:
重庆市社会民生科技创新专项(CSTC2015shmszx120089)
LIN Lu, ZHANG Meng. Advance of Glycoprotein IIb/IIIa Antagonist in Acute Ischemic Stroke[J]. Chinese Journal of Stroke, 2016, 11(08): 697-703.
林露,张猛. 血小板糖蛋白Ⅱb/Ⅲa受体拮抗剂治疗急性缺血性卒中的研究进展[J]. 中国卒中杂志, 2016, 11(08): 697-703.
1 Liu L,Wang D,Wong KS,et al. Stroke and strokecare in China:huge burden,significant workload,and a national priority[J]. Stroke,2011,42:3651-3654.2 Bennett JS. Structure and function of the plateletintegrin alpha IIb beta3[J]. J Clin Invest,2005,115:3363-3369.3 中华医学会心血管病学分会,中华心血管病杂志编辑委员会. 抗血小板治疗中国专家共识[J]. 中华心血管病杂志,2013,41:183-194.4 Nu rde n AT,Caen JP. An abnormal plateletglycoprotein pattern in three cases of Glanzmann'sthrombasthenia[J]. Br J Haematol,1974,28:253-260.5 Kumar S,Rajshekher G,Prabhakar S. Plateletglycoprotein Ⅱb/Ⅲa inhibitors in acute ischemicstroke[J]. Neurol India,2008,56:399-404.6 Coller BS. Anti-GPⅡb/Ⅲa drugs:current strategiesand future directions[J]. Thromb Haemost,2001,86:427-443.7 Casserly IP,Topol EJ. Glycoprotein Ⅱb/Ⅲaantagonists--from bench to practice[J]. Cell Mol LifeSci,2002,59:478-500.8 Pancioli AM,Brott TG. Therapeutic potential ofplatelet glycoprotein Ⅱb/Ⅲa receptor antagonistsin acute ischaemic stroke:scientific rationale andavailable evidence[J]. CNS Drugs,2004,18:981-988. 9 Béguin S,Kumar R,Keular ts I,et al. Fibr independentplatelet procoagulant activity requiresGPIb receptors and von Willebrand factor[J]. Blood,1999,93:564-570.10 Me r l i n i PA,Ros s i M,Men o z z i A,e t a l .Thrombocytopenia caused by abciximab or tirofibanand its association with clinical outcome in patientsundergoing coronary stenting[J]. Circulation,2004,109:2203-2206.11 Llevadot J,Coulter SA,Giugliano RP. A practicalapproach to the diagnosis and management ofthrombocytopenia associated with glycoprotein Ⅱb/Ⅲareceptor inhibitors[J]. J Thromb Thrombolysis,2000,9:175-180.12 Tcheng JE,Harrington RA,Kottke-Marchant K,etal. Multicenter,randomized,double-blind,placebocontrolledtrial of the platelet integrin glycoproteinⅡb/Ⅲa blocker integrelin in elective coronaryintervention. IMPACT Investigators[J]. Circulation,1995,91:2151-2157.13 Goa KL,Noble S. Eptifibatide:a review of its usein patients with acute coronary syndromes and/orundergoing percutaneous coronary intervention[J].Drugs,1999,57:439-462.14 Torgano G,Zecca B,Monzani V,et al. Effect ofintravenous tirofiban and aspirin in reducing shorttermand long-term neurologic deficit in patients withischemic stroke:a double-blind randomized trial[J].Cerebrovasc Dis,2010,29:275-281.15 Alexander KP,Chen AY,Newby LK,et al. Sexdifferences in major bleeding with glycoproteinⅡb/Ⅲa inhibitors:results f rom the CRUSADE(Can Rapid risk stratification of Unstable anginapatients Suppress ADverse outcomes with Earlyimplementat ion of the ACC/AHA guidelines)initiative[J]. Circulation,2006,114:1380-1387.16 Gurm HS,Smith DE,Collins JS,et al. The relativesafety and efficacy of abciximab and eptifibatide inpatients undergoing primary percutaneous coronaryintervention:insights from a large regional registry ofcontemporary percutaneous coronary intervention[J].J Am Coll Cardiol,2008,51:529-535.17 Roffi M,Moliterno DJ,Meier B,et al. Impact ofdifferent platelet glycoprotein Ⅱb/Ⅲa receptorinhibitors among diabetic patients undergoingpercutaneous coronary intervention:Do Tirofibanand ReoPro Give Similar Efficacy Outcomes Trial(TARGET) 1-year follow-up[J]. Circulation,2002,105:2730-2736.18 A comparison of aspirin plus tirofiban with aspirinplus heparin for unstable angina. Platelet ReceptorInhibition in Ischemic Syndrome Management(PRISM) Study Investigators[J]. N Engl J Med,1998,338:1498-1505.19 Kastrati A,Mehilli J,Neumann FJ,et al. Abciximabin patients with acute coronary syndromes undergoingpercutaneous coronary intervention after clopidogrelpretreatment:the ISAR-REACT 2 randomized trial[J].JAMA,2006,295:1531-1538.20 Van't Hof AW,Ten Berg J,Heestermans T,et al.Prehospital initiation of tirofiban in patients with STelevationmyocardial infarction undergoing primaryangioplasty (On-TIME 2):a multicentre,double-blind,randomised controlled trial[J]. Lancet,2008,372:537-546.21 Wang TY,White JA,Tricoci P,et al. Upstreamclopidogrel use and the efficacy and safety of earlyeptifibatide treatment in patients with acute coronarysyndrome:an analysis from the Early GlycoproteinⅡb/Ⅲa Inhibition in Patients with Non-ST-SegmentElevation Acute Coronary Syndrome (EARLY ACS)trial[J]. Circulation,2011,123:722-730.22 P r id e YB,Mohanave lu S,Zork u n C,e t a l .Association between angiographic complications andclinical outcomes among patients with acute coronarysyndrome undergoing percutaneous coronaryintervention:an EARLYACS (Early GlycoproteinⅡb/Ⅲa Inhibition in Non-ST-Segment ElevationAcute Coronary Syndrome) angiographic substudy[J].JACC Cardiovasc Interv,2012,5:927-935.23 Abciximab Emergent St roke Treatment Tr ial(AbESTT) Investigators. Emergency administrationof abciximab for treatment of patients with acuteischemic stroke:results of a randomized phase 2trial[J]. Stroke,2005,36:880-890.24 Adams HP Jr,Effron MB,Torner J,et al. Emergencyadministration of abciximab for treatment of patientswith acute ischemic stroke:results of an internationalphase Ⅲ trial:Abciximab in Emergency Treatment ofStroke Trial (AbESTT-Ⅱ)[J]. Stroke,2008,39:87-99.25 Stead LG,Vaidyanathan L. Evidence-basedemergency medicine/systematic review abstract. Roleof abciximab in the management of acute ischemicstroke[J]. Ann Emerg Med,2009,53:392-394.26 Siebler M,Hennerici MG,Schneider D,et al. Safetyof Tirofiban in acute Ischemic Stroke:the SaTIStrial[J]. Stroke,2011,42:2388-2392.27 Ciccone A,Motto C,Abraha I,et al. GlycoproteinⅡb-Ⅲa inhibitors for acute ischaemic stroke[J].Cochrane Database Syst Rev,2014,3:CD005208.28 Skagervik I,Wikholm G,Rosengren L,et al. BrainCT perfusion in stroke in progression[J]. Eur Neurol,2008,59:98-100.29 Philipps J,Thomalla G,Glahn J,et al. Treatment ofprogressive stroke with tirofiban--experience in 35patients[J]. Cerebrovasc Dis,2009,28:435-438.30 Mar tin-Schild S,Shaltoni H,Abraham AT,etal. Safety of eptifibatide for subcortical strokeprogression[J]. Cerebrovasc Dis,2009,28:595-600.31 Rha JH,Saver JL. The impact of recanalization onischemic stroke outcome:a meta-analysis[J]. Stroke,2007,38:967-973.32 Alexandrov AV,Grotta JC. Arterial reocclusionin stroke patients treated with intravenous tissueplasminogen activator[J]. Neurology,2002,59:862-867.33 Mendonca N,Rodriguez-Luna D,Rubiera M,etal. Predictors of tissue-type plasminogen activatornonresponders according to location of vesselocclusion[J]. Stroke,2012,43:417-421.34 Zinkstok SM,Roos YB,ARTIS investigators. Earlyadministration of aspirin in patients treated withalteplase for acute ischaemic stroke:a randomisedcontrolled trial[J]. Lancet,2012,380:731-737.35 Straub S,Junghans U,Jovanovic V,et al. Systemicthrombolysis with recombinant tissue plasminogenactivator and tirofiban in acute middle cerebral arteryocclusion[J]. Stroke,2004,35:705-709.36 Seitz RJ,Sukiennik J,Siebler M. Outcome aftersystemic thrombolysis is predicted by age and strokeseverity:an open label experience with recombinanttissue plasminogen activator and tirofiban[J]. NeurolInt,2012,4:e9.37 Pancioli AM,Broder ick J,Brott T,et al. Thecombined approach to lysis utilizing eptifibatide andrt-PA in acute ischemic stroke:the CLEAR stroketrial[J]. Stroke,2008,39:3268-3276.38 Pancioli AM,Adeoye O,Schmit PA,et al. Combinedapproach to lysis utilizing eptifibatide and recombinanttissue plasminogen activator in acute ischemic strokeenhancedregimen stroke trial[J]. Stroke,2013,44:2381-2387.39 Adeoye O,Knight WA,Khoury J,et al. A matchedcomparison of eptifibatide plus rt-PA versus rt-PA alone in acute ischemic stroke[J]. J StrokeCerebrovasc Dis,2014,23:e313-315.40 Adeoye O,Sucharew H,Khoury J,et al. Combinedapproach to lysis utilizing eptifibatide and recombinanttissue-type plasminogen activator in acute ischemicstroke-full dose regimen stroke trial[J]. Stroke,2015,46:2529-2533.41 Fransen PS,Beumer D,Berkhemer OA,et al.MRCLEAN,a multicenter randomized clinical trialof endovascular treatment for acute ischemic strokein the Netherlands:study protocol for a randomizedcontrolled trial[J]. Trials,2014,15:343.42 Goya l M,Demchu k AM,Menon BK,e t a l .Randomized assessment of rapid endovasculartreatment of ischemic stroke[J]. N Engl J Med,2015,372:1019-1030.43 Campbell BC,Mitchell PJ,Yan B,et al. A multicenter,randomized,controlled study to investigate EXtendingthe time for Thrombolysis in Emergency NeurologicalDeficits with Intra-Arterial therapy (EXTEND-I)[J]. InJ Stroke,2014,9:126-132.44 Qu r e s h i A I,Si dd i qu i AM,Kim SH,e t a l .Reocclusion of recanalized arteries during intraarterialthrombolysis for acute ischemic stroke[J].AJNR Am J Neuroradiol,2004,25:322-328.45 Heo JH,Lee KY,Kim SH,et al. Immediatereocclusion following a successful thrombolysis inacute stroke:a pilot study[J]. Neurology,2003,60:1684-1687.46 Janjua N,Alkawi A,Suri MF,et al. Impact ofarterial reocclusion and distal fragmentation duringthrombolysis among patients with acute ischemicstroke[J]. AJNR Am J Neuroradiol,2008,29:253-258.47 Ries T,Siemonsen S,Grzyska U,et al. Abciximab is a safe rescue therapy in thromboembolic eventscomplicating cerebral aneurysm coil embolization:single center experience in 42 cases and review of theliterature[J]. Stroke,2009,40:1750-1757.48 Saedon M,Singer DR,Pang R,et al. Registry reporton kinetics of rescue antiplatelet treatment to abolishcerebral microemboli after carotid endarterectomy[J].Stroke,2013,44:230-233.49 Velat GJ,Burry MV,Eskioglu E,et al. The useof abciximab in the treatment of acute cerebralthromboembolic events during neuroendovascularprocedures[J]. Surg Neurol,2006,65:352-358,discussion 358-359.50 Kim JW,Jeon P,Kim GM,et al. Local intraarterialtirofiban after formation of anterograde f low inpatients with acute ischemic stroke:preliminaryexperience and short term follow-up results[J]. ClinNeurol Neurosurg,2012,114:1316-1319.51 Seo JH,Jeong HW,Kim ST,et al. Adjuvant tirofibaninjection through deployed solitaire stent as arescuetechnique after failed mechanical thrombectomy inacute stroke[J]. Neurointervention,2015,10:22-27.52 中华医学会神经病学分会,中华医学会神经病学分会神经血管介入协作组,急性缺血性卒中介入诊疗指南撰写组. 中国急性缺血性卒中早期血管内介入诊疗指南[J]. 中国神经科杂志,2015,48:356-361. |
[1] | WANG Xiaorui, LUO Song, ZOU Liangyu, QU Hongdang, CUI Xue, ZHAO Yujie. Value of Eosinophil-to-Monocyte Ratio in Predicting the Prognosis of Patients with Acute Ischemic Stroke Receiving Intravenous Thrombolysis [J]. Chinese Journal of Stroke, 2024, 19(9): 1025-1033. |
[2] | ABULANIYAZI Anaguli, WU Xiaoxin, LI Jiaoxing, LI Zhuhao, SHENG Wenli. Research Progress on Factors Related to the Susceptibility Vessel Sign and its Clinical Application in Acute Ischemic Stroke [J]. Chinese Journal of Stroke, 2024, 19(9): 1077-1085. |
[3] | WU Chunyan, YIN Yashi, WANG Guangzhi, YUE Kuitao. Evaluation and Application of Medical Imaging for Acute Ischemic Stroke at Different Time Windows: A Review [J]. Chinese Journal of Stroke, 2024, 19(9): 1094-1101. |
[4] | YI Luo, JIANG Yingyu, MENG Xia, JIANG Yong, WANG Yongjun, GU Hongqiu. Development and Validation of a Prediction Model of In-Hospital Neurological Deterioration for Patients with Minor Acute Ischemic Stroke [J]. Chinese Journal of Stroke, 2024, 19(5): 524-531. |
[5] | ZHENG Guomin, LIANG Zhigang, ZHANG Zhen. Research Progress of Tirofiban Combined with Mechanical Thrombectomy in the Treatment of Acute Ischemic Stroke [J]. Chinese Journal of Stroke, 2024, 19(5): 573-578. |
[6] | HAO Manjun, WANG Liyuan, XIONG Yunyun. Neuroimaging Evaluation of Reperfusion Therapy [J]. Chinese Journal of Stroke, 2024, 19(4): 459-467. |
[7] | YAN Xige, WANG Guoling, ZHANG Bogang, PENG Min, DONG Zhongjun, SHEN Xiaoping, CHEN Xiuxiao, JIA Qian, DONG Huige, CHENG Li. A Rescue Therapy for Vascular Reocclusion after Carotid Artery Stenting for Acute Carotid Artery Occlusion—Femoral-Carotid Artery Bypass [J]. Chinese Journal of Stroke, 2024, 19(3): 331-336. |
[8] | LIU Yafei, WU Tingting, YAN Shixi, JIA Chong, ZHANG Hanfei, ZHANG Zhongbo, WU Yiping. Progress in Imaging Assessment of Infarct Core Volume in Acute Ischemic Stroke [J]. Chinese Journal of Stroke, 2024, 19(3): 349-355. |
[9] | YANG Jiajie, ZHANG Liang, HUANG Li’an. Advances in Pharmacogenomics-Based Individualized Antithrombotic Therapy for Acute Ischemic Stroke [J]. Chinese Journal of Stroke, 2024, 19(10): 1111-1117. |
[10] | CHEN Xubin, XIAO Weiting, YUE Xifeng, HE Nengqing, ZENG Xiaohui. Relationship between Serum MicroRNA-874-3p, MicroRNA-181a-5p, Wnt/β-catenin Signaling Pathway and Neurological Function Prognosis in Patients with Acute Ischemic Stroke after Intravenous Thrombolysis [J]. Chinese Journal of Stroke, 2024, 19(10): 1162-1169. |
[11] | YANG Jiaxin, HE Chunyu, LIU Lei, CHEN Wenbo, XIE Yan. Prediction Models of Symptomatic Intracerebral Hemorrhage after Intravenous Thrombolysis in Acute Ischemic Stroke: A Systematic Review [J]. Chinese Journal of Stroke, 2024, 19(1): 76-86. |
[12] | LU Jing, LI Chuanfa, ZHANG Daqi, CHEN Rong, LI Qifu. Research Progress of Hemorrhagic Transformation after Endovascular Treatment in Acute Ischemic Stroke [J]. Chinese Journal of Stroke, 2023, 18(9): 1065-1072. |
[13] | ZHOU Yumeng, CHEN Lixia. Progress on Blood Pressure Management in Patients with Acute Ischemic Stroke Undergoing Mechanical Thrombectomy [J]. Chinese Journal of Stroke, 2023, 18(9): 1073-1078. |
[14] | FAN Ping, YUE Kuitao, LI Aiyuan, ZHAO Zhe, XIE Hai, WU Chunyan ( Contributed equally). . Review of the Application of Radiomics in Acute Ischemic Stroke [J]. Chinese Journal of Stroke, 2023, 18(8): 952-957. |
[15] | HAO Manjun, CAO Zhixin, LI Guangshuo, XIONG Yunyun. Interpretation of the Keypoints and Updates on National Clinical Guideline for Stroke for the United Kingdom and Ireland (Edition 2023) —Ischemic Stroke [J]. Chinese Journal of Stroke, 2023, 18(12): 1357-1364. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||